AR106012A1 - COMPOSITIONS AND METHODS TO USE ANTI-IL-34 ANTIBODIES TO TREAT NEUROLOGICAL DISEASES - Google Patents
COMPOSITIONS AND METHODS TO USE ANTI-IL-34 ANTIBODIES TO TREAT NEUROLOGICAL DISEASESInfo
- Publication number
- AR106012A1 AR106012A1 ARP160101617A ARP160101617A AR106012A1 AR 106012 A1 AR106012 A1 AR 106012A1 AR P160101617 A ARP160101617 A AR P160101617A AR P160101617 A ARP160101617 A AR P160101617A AR 106012 A1 AR106012 A1 AR 106012A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- disease
- human
- amino acid
- acid residues
- Prior art date
Links
Abstract
Reivindicación 1: Un método para tratar una enfermedad neurológica en un individuo, que comprende administrar al individuo una cantidad efectiva de un anticuerpo anti-IL-34. Reivindicación 4: El método de acuerdo con cualquiera de las reivindicaciones 1 - 3, en donde el anticuerpo anti-IL-34 es un anticuerpo aislado que se une al IL-34 humano, el cual anticuerpo se une a un epítope que comprende por lo menos uno de entre los residuos de aminoácidos Glu103, Leu109, Gln106, Asn150, Leu127, Asn128, Ser184, Leu186, Asn187, Lys44, Glu121, Asp107, Glu111, Ser104, Gln120, Trp116 y Asn61 de un IL-34 humano, en donde la posición de los residuos de aminoácidos se basa en su posición en la SEQ ID Nº 1, en donde el anticuerpo inhibe la unión entre el IL-34 humano y el CSF-1R humano. Reivindicación 84: Un kit que comprende una composición farmacéutica que comprende un anticuerpo anti-IL-34 y un vehículo farmacéuticamente aceptable. Reivindicación 89: El kit de acuerdo con la reivindicación 88, en donde la enfermedad neurológica se selecciona de entre el grupo consistente: en la enfermedad de Alzheimer, la enfermedad de Parkinson, la enfermedad de Huntington, la esclerosis lateral amiotrófica, dolor neuropático, enfermedad priónica, ataxia espinocerebelar, atrofia muscular espinal, autismo y trastornos del espectro de autismo.Claim 1: A method of treating a neurological disease in an individual, comprising administering to the individual an effective amount of an anti-IL-34 antibody. Claim 4: The method according to any one of claims 1-3, wherein the anti-IL-34 antibody is an isolated antibody that binds to human IL-34, which antibody binds to an epitope comprising minus one of the amino acid residues Glu103, Leu109, Gln106, Asn150, Leu127, Asn128, Ser184, Leu186, Asn187, Lys44, Glu121, Asp107, Glu111, Ser104, Gln120, Trp116 and Asn61 of a human IL-34 The position of amino acid residues is based on their position in SEQ ID No. 1, where the antibody inhibits the binding between human IL-34 and human CSF-1R. Claim 84: A kit comprising a pharmaceutical composition comprising an anti-IL-34 antibody and a pharmaceutically acceptable carrier. Claim 89: The kit according to claim 88, wherein the neurological disease is selected from the group consisting of: in Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, neuropathic pain, disease prion, spinocerebellar ataxia, spinal muscular atrophy, autism and autism spectrum disorders.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562170069P | 2015-06-02 | 2015-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106012A1 true AR106012A1 (en) | 2017-12-06 |
Family
ID=60931755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101617A AR106012A1 (en) | 2015-06-02 | 2016-06-02 | COMPOSITIONS AND METHODS TO USE ANTI-IL-34 ANTIBODIES TO TREAT NEUROLOGICAL DISEASES |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR106012A1 (en) |
-
2016
- 2016-06-02 AR ARP160101617A patent/AR106012A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019006657A2 (en) | Anti-CD73 antibodies and uses thereof | |
MD3261720T2 (en) | Antibodies to Tau and uses thereof | |
AR104213A1 (en) | ANTI-BODIES ANTI-CD38 AS THERAPEUTIC AGENTS | |
PE20181049A1 (en) | AGENTS, USES AND METHODS FOR THE TREATMENT OF SINUCLEINOPATHY | |
ECSP088530A (en) | SPECIFIC MONOCLONAL ANTIBODIES Aß 1-42 WITH THERAPEUTIC PROPERTIES | |
WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
PE20061040A1 (en) | HUMANIZED ANTIAMYLLOID ANTIBODIES | |
AR107290A1 (en) | PEPTIDE ANTIBODIES b AMILOID ANTI-N3pGlu AND USES OF THE SAME | |
MX356800B (en) | Humanized tau antibody. | |
MX2019000047A (en) | Structure-based peptide inhibitors of alpha-synuclein aggregation. | |
MX2023005465A (en) | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors. | |
MX2019000864A (en) | Histone acetyltransferase activators and compositions and uses thereof. | |
CO6640211A2 (en) | A-beta peptide compositions and methods | |
MX2019006495A (en) | Treatment of neurological diseases. | |
CL2019001749A1 (en) | Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis. | |
PH12017502020A1 (en) | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor | |
EA202190807A1 (en) | ANTIBODIES TO SYNUCLEINE | |
BR112017020769A2 (en) | antibody or binding fragment, sequence no: 3 or sequence no: 7, antibody-drug conjugate (adc), pharmaceutical composition, process for producing the pharmaceutical composition, kit for diagnosing an individual suffering from a neurodegenerative disorder, method to diagnose an individual suffering from a neurodegenerative disorder, use of antibody or binding fragment, ex vivo use of a t14 peptide, method of identifying a candidate agent, method of identifying an agent, method of identifying a modulating agent | |
CL2020000070A1 (en) | Agents, uses and methods for treatment. | |
MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
MX2018001592A (en) | Compositions and methods for treating and preventing neurodegenerative disorders. | |
AR106012A1 (en) | COMPOSITIONS AND METHODS TO USE ANTI-IL-34 ANTIBODIES TO TREAT NEUROLOGICAL DISEASES | |
MX2021011596A (en) | Compounds and compositions as modulators of tlr signaling. | |
EA202192488A1 (en) | ANTIBODIES AGAINST TSG-6 AND THEIR APPLICATIONS | |
BR112017011226A2 (en) | peptide, pharmaceutical composition, pharmaceutical composition manufacturing process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |